FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308180693> ?p ?o ?g. }

• W4308180693 endingPage "1556" @default.
• W4308180693 startingPage "1549" @default.
• W4308180693 abstract "An oral fixed-dose combination of relugolix/estradiol/norethisterone (also known as norethindrone) acetate (Ryeqo®; Myfembree®) has been approved for the management of heavy menstrual bleeding associated with uterine fibroids in the USA and management of moderate to severe symptoms of uterine fibroids in the EU. Relugolix is a gonadotropin releasing hormone (GnRH) receptor antagonist that decreases serum estradiol and progesterone concentrations to postmenopausal levels. The addition of estradiol/norethisterone acetate to relugolix ameliorates relugolix-induced bone loss and hot flush. In the two phase 3 LIBERTY trials, relugolix + estradiol/norethisterone substantially decreased menstrual bleeding and improved a range of other uterine fibroid symptoms in women with uterine fibroids-associated heavy menstrual bleeding. The combination was generally well tolerated, with vasomotor symptoms being the most common adverse reaction. Treatment with this combination for over up to 2 years did not induce a clinically meaningful bone loss in the majority of women. Relugolix/estradiol/norethisterone acetate, with its convenient once-daily administration, is a useful addition to current pharmacological treatment options for premenopausal women with symptomatic uterine fibroids. Uterine fibroids are a common type of noncancerous tumours that grow in the uterus. In some women, these tumours cause debilitating symptoms, such as heavy menstrual bleeding, pelvic pain and passing of blood clots. Hysterectomy is the only definitive treatment for this condition, but is associated with some disadvantages. Less invasive procedures and medical treatments are now available to treat these symptoms. Recently, a fixed-dose tablet comprising relugolix, estradiol and norethisterone acetate (Ryeqo®; Myfembree®) has been approved to treat symptoms of uterine fibroids. This combination works by suppressing ovarian hormone levels. In clinical trials, relugolix + estradiol/norethisterone substantially reduced menstrual bleeding and improved several other symptoms in women with uterine fibroids-associated heavy menstrual bleeding. The combination was generally well tolerated and had a minimal impact on bone loss, a known adverse effect of such therapies. With its convenient once-daily administration, relugolix/estradiol/norethisterone acetate is a useful addition to current medical treatment options for premenopausal women with symptomatic uterine fibroids." @default.
• W4308180693 created "2022-11-08" @default.
• W4308180693 creator A5077298201 @default.
• W4308180693 date "2022-10-01" @default.
• W4308180693 modified "2023-10-14" @default.
• W4308180693 title "Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids" @default.
• W4308180693 cites W1970099367 @default.
• W4308180693 cites W1979091123 @default.
• W4308180693 cites W2008203144 @default.
• W4308180693 cites W2016927496 @default.
• W4308180693 cites W2043821663 @default.
• W4308180693 cites W2595206985 @default.
• W4308180693 cites W2602082991 @default.
• W4308180693 cites W2765546885 @default.
• W4308180693 cites W2914196959 @default.
• W4308180693 cites W2978453381 @default.
• W4308180693 cites W3002354512 @default.
• W4308180693 cites W3093256145 @default.
• W4308180693 cites W3129366643 @default.
• W4308180693 cites W3201008890 @default.
• W4308180693 cites W3201340799 @default.
• W4308180693 cites W3201359418 @default.
• W4308180693 cites W3211275990 @default.
• W4308180693 cites W4210998728 @default.
• W4308180693 cites W4220889066 @default.
• W4308180693 cites W4255664903 @default.
• W4308180693 cites W4293094381 @default.
• W4308180693 doi "https://doi.org/10.1007/s40265-022-01790-4" @default.
• W4308180693 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36331779" @default.
• W4308180693 hasPublicationYear "2022" @default.
• W4308180693 type Work @default.
• W4308180693 citedByCount "5" @default.
• W4308180693 countsByYear W43081806932023 @default.
• W4308180693 crossrefType "journal-article" @default.
• W4308180693 hasAuthorship W4308180693A5077298201 @default.
• W4308180693 hasBestOaLocation W43081806931 @default.
• W4308180693 hasConcept C126322002 @default.
• W4308180693 hasConcept C126894567 @default.
• W4308180693 hasConcept C197934379 @default.
• W4308180693 hasConcept C2777486506 @default.
• W4308180693 hasConcept C2777687323 @default.
• W4308180693 hasConcept C2779076696 @default.
• W4308180693 hasConcept C2779279991 @default.
• W4308180693 hasConcept C2780159708 @default.
• W4308180693 hasConcept C2780566971 @default.
• W4308180693 hasConcept C2780835420 @default.
• W4308180693 hasConcept C2781039349 @default.
• W4308180693 hasConcept C2908647359 @default.
• W4308180693 hasConcept C29456083 @default.
• W4308180693 hasConcept C2986817661 @default.
• W4308180693 hasConcept C71315377 @default.
• W4308180693 hasConcept C71924100 @default.
• W4308180693 hasConcept C99454951 @default.
• W4308180693 hasConceptScore W4308180693C126322002 @default.
• W4308180693 hasConceptScore W4308180693C126894567 @default.
• W4308180693 hasConceptScore W4308180693C197934379 @default.
• W4308180693 hasConceptScore W4308180693C2777486506 @default.
• W4308180693 hasConceptScore W4308180693C2777687323 @default.
• W4308180693 hasConceptScore W4308180693C2779076696 @default.
• W4308180693 hasConceptScore W4308180693C2779279991 @default.
• W4308180693 hasConceptScore W4308180693C2780159708 @default.
• W4308180693 hasConceptScore W4308180693C2780566971 @default.
• W4308180693 hasConceptScore W4308180693C2780835420 @default.
• W4308180693 hasConceptScore W4308180693C2781039349 @default.
• W4308180693 hasConceptScore W4308180693C2908647359 @default.
• W4308180693 hasConceptScore W4308180693C29456083 @default.
• W4308180693 hasConceptScore W4308180693C2986817661 @default.
• W4308180693 hasConceptScore W4308180693C71315377 @default.
• W4308180693 hasConceptScore W4308180693C71924100 @default.
• W4308180693 hasConceptScore W4308180693C99454951 @default.
• W4308180693 hasIssue "15" @default.
• W4308180693 hasLocation W43081806931 @default.
• W4308180693 hasLocation W43081806932 @default.
• W4308180693 hasLocation W43081806933 @default.
• W4308180693 hasLocation W43081806934 @default.
• W4308180693 hasOpenAccess W4308180693 @default.
• W4308180693 hasPrimaryLocation W43081806931 @default.
• W4308180693 hasRelatedWork W1977786404 @default.
• W4308180693 hasRelatedWork W1981675177 @default.
• W4308180693 hasRelatedWork W1985351698 @default.
• W4308180693 hasRelatedWork W2002242365 @default.
• W4308180693 hasRelatedWork W2019412650 @default.
• W4308180693 hasRelatedWork W2063547238 @default.
• W4308180693 hasRelatedWork W2129994109 @default.
• W4308180693 hasRelatedWork W2318094389 @default.
• W4308180693 hasRelatedWork W4308180693 @default.
• W4308180693 hasRelatedWork W4309890756 @default.
• W4308180693 hasVolume "82" @default.
• W4308180693 isParatext "false" @default.
• W4308180693 isRetracted "false" @default.
• W4308180693 workType "article" @default.